company background image
0RGI logo

Cosmo Pharmaceuticals LSE:0RGI Stock Report

Last Price

CHF68.53

Market Cap

CHF1.1b

7D

7.7%

1Y

20.1%

Updated

28 Mar, 2024

Data

Company Financials +

Cosmo Pharmaceuticals N.V.

LSE:0RGI Stock Report

Market Cap: CHF1.1b

0RGI Stock Overview

Cosmo Pharmaceuticals N.V., a specialty pharmaceutical company, focuses on the development and commercialization products for gastroenterology, endoscopy, dermatology, and healthtech worldwide.

0RGI fundamental analysis
Snowflake Score
Valuation1/6
Future Growth5/6
Past Performance1/6
Financial Health5/6
Dividends2/6

Cosmo Pharmaceuticals N.V. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Cosmo Pharmaceuticals
Historical stock prices
Current Share PriceCHF68.53
52 Week HighCHF70.70
52 Week LowCHF33.75
Beta1.2
1 Month Change3.89%
3 Month Change33.59%
1 Year Change20.06%
3 Year Change-17.53%
5 Year Change-23.81%
Change since IPO-60.61%

Recent News & Updates

Recent updates

Shareholder Returns

0RGIGB PharmaceuticalsGB Market
7D7.7%4.8%2.3%
1Y20.1%2.5%2.7%

Return vs Industry: 0RGI exceeded the UK Pharmaceuticals industry which returned 0.6% over the past year.

Return vs Market: 0RGI exceeded the UK Market which returned 3.7% over the past year.

Price Volatility

Is 0RGI's price volatile compared to industry and market?
0RGI volatility
0RGI Average Weekly Movement4.3%
Pharmaceuticals Industry Average Movement9.5%
Market Average Movement4.8%
10% most volatile stocks in GB Market11.3%
10% least volatile stocks in GB Market2.5%

Stable Share Price: 0RGI's share price has been volatile over the past 3 months.

Volatility Over Time: 0RGI's weekly volatility (4%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1997319Alessandro Della Chahttps://www.cosmopharma.com

Cosmo Pharmaceuticals N.V., a specialty pharmaceutical company, focuses on the development and commercialization products for gastroenterology, endoscopy, dermatology, and healthtech worldwide. The company offers Lialda/Mezavant/Mesavancol, a once-daily mesalamine tablet approved to help get active, mild to moderate ulcerative colitis into remission; Lumeblue (methylene blue MMX), a diagnostic drug to enhance pre-cancerous and cancerous detection of colorectal lesions during colonoscopy; Uceris/Cortiment, an oral tablet formulation which delivers budesonide directly to the lumen of the colon; Aemcolo/Relafalk, a GI antibiotic with MMX® technology and is approved for the treatment of travellers’ diarrhoea; Winlevi, a prescription medicine used on the skin to treat acne vulgaris; Eleview, a medical device, which enables the safer and faster removal of colonic lesions; and GI Genius, a system that uses artificial intelligence to detect colorectal polyps during colonoscopy. It is also in the development of Breezula (clascoterone), a novel androgen receptor inhibitor that targets androgen receptors in the scalp, currently expecting phase III trials; Rifamycin SV MMX – IBS-D, a formulation to treat colonic infections and irritable bowel syndrome with diarrhoea, currently completed phase II proof of concept clinical trials; CB-03-10 (cortexolone 17 -valerate-21-propionate), an oral androgen receptor antagonist for treatment solid tumors, currently under phase I studies; and CB-01-33 (colesevelam) for the treatment of bile acid diarrhea, currently under preclinical studies.

Cosmo Pharmaceuticals N.V. Fundamentals Summary

How do Cosmo Pharmaceuticals's earnings and revenue compare to its market cap?
0RGI fundamental statistics
Market capCHF1.12b
Earnings (TTM)CHF1.12m
Revenue (TTM)CHF94.74m

998.8x

P/E Ratio

11.8x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
0RGI income statement (TTM)
Revenue€96.72m
Cost of Revenue€39.34m
Gross Profit€57.38m
Other Expenses€56.24m
Earnings€1.15m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

Apr 30, 2024

Earnings per share (EPS)0.071
Gross Margin59.33%
Net Profit Margin1.19%
Debt/Equity Ratio0.1%

How did 0RGI perform over the long term?

See historical performance and comparison

Dividends

2.8%

Current Dividend Yield

2,808%

Payout Ratio
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.